BioMarin Pharma (BMRN) Tops Q4 EPS by 29c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $62.35 -1.61%
Revenue Growth %: +31.4%
Financial Fact:
INCOME FROM OPERATIONS: -60.09M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +31.4%
Financial Fact:
INCOME FROM OPERATIONS: -60.09M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.49, $0.29 better than the analyst estimate of $0.20. Revenue for the quarter came in at $646.2 million versus the consensus estimate of $639.26 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $2.60-$2.80, versus the consensus of $2.83. BioMarin Pharma sees FY2024 revenue of $2.7-2.8 billion, versus the consensus of $2.82 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
- Aytu BioScience (AYTU) Tops Q4 EPS by 28c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
